Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, spotlights key lung cancer updates from ESMO25.
“Impressive results from MDT-BRIDGE at ESMO25 from Dr. Martin Reck.
Patients with resectable or borderline had 2 cycles of Durvalumab + chemo, then reassessed at MDT. If resectable at start, 95% remained resectable. If borderline, 82% were then felt to be resectable.”
“Nice perspective in discussion by Dr. Corinne Faivre-Finn at ESMO25 on SKYSCRAPER-03, where adding tiragolumab did not improve outcomes over standard PACIFIC and MDT-BRIDGE, reassured by only 5% of people not having either surgery or definitive chemoradiation.”
“Dr. Martin Wermke at ESMO25 presents phase Ib DeLLphi-303, which adds Tarlatamab to chemo-IO in ES SCLC with cycle 2 and in maintenance. Fantastic efficacy – OS and PFS far greater than historic controls, though a highly selected population.”
Safety reassuring – CRS generally low grade and early, and ICANS rare. Most TRAEs are chemotherapy-related. Spider plot shows response patterns – generally rapid response and impressive durability.
“Dr. Noemi Reguart discusses tarlatamab in SCLC at ESMO25. Outlines rationale and is very reassuring to see consistency from other efforts. Will the use of T Cell engagers be the future for all eligible patients with SCLC?”
“Dr. Zosia Piotrowska discusses NORTHSTAR at ESMO25 – impressive PFS benefit in EGFR NSCLC when local consolidation therapy is added, but notable heterogeneity.
Patient selection is an important need for uniform definitions, biomarkers (radiomics?). Encouraging results here.”
More posts featuring Stephen V Liu on OncoDaily.
